Getinge completes the acquisition of Paragonix Technologies
Getinge has completed the acquisition of Paragonix Technologies, a leading U.S. company in organ transport products and services, for an estimated total of USD 477 million. The deal includes an upfront payment of USD 253 million and potential earn-outs of up to USD 224 million between 2024 and 2026. The acquisition is expected to have a slightly negative impact on Getinge's adjusted earnings per share in 2024, but a positive contribution is anticipated starting in 2028.
The acquisition aims to capitalize on the rapidly growing transplant market, which is projected to exceed USD 10 billion by 2034. Paragonix Technologies has shown significant growth, with a 136% increase in 2023. Their organ preservation devices have demonstrated impressive clinical outcomes, including a 50% reduction in severe complications and a 43% reduction in 2-year mortality for heart transplants compared to traditional methods.
Getinge ha completato l'acquisizione di Paragonix Technologies, una delle principali aziende statunitensi nel settore dei prodotti e servizi di trasporto organi, per un totale stimato di 477 milioni di USD. L'accordo prevede un pagamento iniziale di 253 milioni di USD e potenziali earn-out fino a 224 milioni di USD tra il 2024 e il 2026. Si prevede che l'acquisizione avrà un impatto leggermente negativo sugli utili per azione rettificati di Getinge nel 2024, ma una contribuzione positiva è attesa a partire dal 2028.
L'acquisizione mira a capitalizzare sul mercato in rapida crescita dei trapianti, che si prevede supererà i 10 miliardi di USD entro il 2034. Paragonix Technologies ha mostrato una crescita significativa, con un aumento del 136% nel 2023. I loro dispositivi di preservazione degli organi hanno dimostrato risultati clinici impressionanti, tra cui una riduzione del 50% delle complicazioni gravi e una riduzione del 43% della mortalità a 2 anni per i trapianti di cuore rispetto ai metodi tradizionali.
Getinge ha completado la adquisición de Paragonix Technologies, una empresa líder en EE. UU. en productos y servicios de transporte de órganos, por un total estimado de 477 millones de USD. El acuerdo incluye un pago inicial de 253 millones de USD y posibles pagos adicionales de hasta 224 millones de USD entre 2024 y 2026. Se espera que la adquisición tenga un ligero impacto negativo en las ganancias ajustadas por acción de Getinge en 2024, pero se anticipa una contribución positiva a partir de 2028.
La adquisición tiene como objetivo capitalizar el rápido crecimiento del mercado de trasplantes, que se proyecta que superará los 10 mil millones de USD para 2034. Paragonix Technologies ha mostrado un crecimiento significativo, con un aumento del 136% en 2023. Sus dispositivos de preservación de órganos han demostrado resultados clínicos impresionantes, incluyendo una reducción del 50% en complicaciones severas y una reducción del 43% en la mortalidad a 2 años para trasplantes de corazón en comparación con los métodos tradicionales.
Getinge는 장기 운송 제품 및 서비스 분야에서 미국의 선도적인 기업인 Paragonix Technologies를 4억 7700만 달러에 인수했습니다. 이번 거래는 2억 5300만 달러의 선급금과 2024년부터 2026년 사이 최대 2억 2400만 달러의 추가 지급이 포함됩니다. 인수는 2024년 Getinge의 조정 주당 수익에 약간의 부정적인 영향을 미칠 것으로 예상되지만, 2028년부터 긍정적인 기여가 예상됩니다.
이번 인수는 2034년까지 100억 달러를 초과할 것으로 예상되는 빠르게 성장하고 있는 이식 시장을 활용하는 것을 목표로 합니다. Paragonix Technologies는 2023년에 136% 증가한 상당한 성장을 보여주었습니다. 그들의 장기 보존 장치는 심장 이식 시 심각한 합병증을 50% 줄이고 2년 사망률을 43% 감소시키는 등 인상적인 임상 결과를 보여주었습니다.
Getinge a finalisé l'acquisition de Paragonix Technologies, une entreprise américaine de premier plan dans le domaine des produits et services de transport d'organes, pour un montant total estimé de 477 millions USD. L'accord comprend un paiement initial de 253 millions USD et des paiements supplémentaires potentiels pouvant atteindre 224 millions USD entre 2024 et 2026. On s'attend à ce que l'acquisition ait un impact légèrement négatif sur les bénéfices ajustés par action de Getinge en 2024, mais une contribution positive est attendue à partir de 2028.
L'acquisition vise à capitaliser sur le marché des transplantations en pleine croissance, qui devrait dépasser 10 milliards USD d'ici 2034. Paragonix Technologies a montré une croissance significative, avec une augmentation de 136% en 2023. Leurs dispositifs de préservation des organes ont démontré des résultats cliniques impressionnants, notamment une réduction de 50% des complications graves et une réduction de 43% de la mortalité à 2 ans pour les greffes de cœur par rapport aux méthodes traditionnelles.
Getinge hat die Übernahme von Paragonix Technologies abgeschlossen, einem führenden US-Unternehmen im Bereich Produkte und Dienstleistungen für den Transport von Organen, für insgesamt geschätzte 477 Millionen USD. Der Deal umfasst eine sofortige Zahlung von 253 Millionen USD und mögliche Zusatzvergütungen von bis zu 224 Millionen USD zwischen 2024 und 2026. Es wird erwartet, dass die Übernahme einen leicht negativen Einfluss auf Getinges bereinigte Erträge pro Aktie im Jahr 2024 haben wird, jedoch wird ab 2028 ein positiver Beitrag erwartet.
Die Übernahme zielt darauf ab, den schnell wachsenden Markt für Transplantationen zu nutzen, der voraussichtlich 10 Milliarden USD bis 2034 überschreiten wird. Paragonix Technologies hat ein signifikantes Wachstum gezeigt, mit einem 136%igen Anstieg im Jahr 2023. Ihre Organspende-Geräte haben beeindruckende klinische Ergebnisse gezeigt, darunter eine 50%ige Reduktion schwerer Komplikationen und eine 43%ige Reduktion der 2-Jahres-Sterblichkeit bei Herztransplantationen im Vergleich zu herkömmlichen Methoden.
- Acquisition of Paragonix Technologies expands Getinge's presence in the rapidly growing transplant market
- Paragonix Technologies demonstrated 136% growth in 2023, outpacing market growth
- Paragonix's heart preservation device reduces severe complications by over 50% and 2-year mortality by 43%
- Potential for global expansion as Paragonix's sales are currently concentrated in the US
- Combination of Paragonix and Getinge's offerings creates a strong portfolio for the global transplant market
- Acquisition expected to have a slightly negative impact on Getinge's adjusted earnings per share in 2024
- Positive contribution to adjusted earnings per share not anticipated until 2028
- Initial payout of USD 253 million financed through a bridge loan, potentially increasing debt
Getinge has today completed the previously announced acquisition of
All conditions for the transaction have now been fulfilled, whereupon the transaction was completed today.
Getinge paid approximately
The deal rationale in brief:
The total market for transplants has been growing rapidly in recent years and is expected to continue to experience double digit growth and exceed
Growth in this market is expected to be driven by volume increase due to demand and the transition from traditional methods (such as ice storage) towards new technologies as the average cost of transplant cases increases. The heart and lung segments have already experienced this trend, and similar development is expected for the abdominal segment.
Paragonix Technologies organ preservation devices and services have seen rapid growth, outgrowing the market significantly in 2023 with
Paragonix Technologies has a strong offering targeting the heart and lung segments; the company's organ preservation device for hearts has been shown to reduce severe complications by over
Paragonix Technologies recently launched attractive offerings targeting the abdominal segment and has a strong pipeline of additional products. The company also has a strong portfolio of digital solutions and services.
As close to
Combining Paragonix Technologies' leading offering and pipeline with Getinge's expertise and offering in the acute heart and lung support, digital technologies, and services creates an attractive portfolio of products and services for the global transplant market. The deal also enables the development of new combined offerings for the future – strengthening the leading position further.
Read the press release from August 22, 2024 >>
Investor Relations:
Lars Mattson, SVP Corporate Development (Corporate Strategy | M&A | Investor Relations)
Phone: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com
Media contact:
Caroline Örmgård, Head of Public & Media Relations
Phone: +46 (0)10 335 0041
Email: caroline.ormgard@getinge.com
About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.
About Paragonix Technologies
Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to preservation that represents a significant improvement over the traditional standard of care. Paragonix Advanced Organ Preservation devices combine clinically-proven, stable cooling techniques with digital tracking and monitoring technologies to provide clinicians complete control and oversight throughout the donor organ journey. The clinical impact of Paragonix preservation technology is reinforced by the GUARDIAN clinical registries, the largest database of organ preservation data in the world that analyzes post-transplant outcomes in transplant recipients.
Find out more about Paragonix Technologies >>
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release - Getinge completes the acquisition of Paragonix Technologies | |
https://news.cision.com/getinge/i/paragonix-1200x628,c3332936 | Paragonix 1200x628 |
View original content:https://www.prnewswire.com/news-releases/getinge-completes-the-acquisition-of-paragonix-technologies-302245117.html
SOURCE Getinge
FAQ
What is the total value of Getinge's acquisition of Paragonix Technologies (GNGBY)?
When will Getinge's acquisition of Paragonix Technologies (GNGBY) start contributing positively to earnings?
What are the clinical benefits of Paragonix Technologies' organ preservation devices?
How much did Paragonix Technologies grow in 2023?
